국가: 영국
언어: 영어
출처: MHRA (Medicines & Healthcare Products Regulatory Agency)
Imidapril hydrochloride
Northumbria Pharma Ltd
C09AA16
Imidapril hydrochloride
20mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050501; GTIN: 5028613001899
: F O T N E M T A E R T E H T N I E C N A T S N I R O F D E S U : S E N I C I D E M Potassium sparing diuretics (water tablets) (spironolactone, triamterene or amiloride) heart failure, liver disease, certain kidney diseases Potassium tablets or liquids or salt substitutes containing potassium low blood levels of potassium Non-potassium sparing diuretics (water tablets) (thiazide_,_ ) e c a f d n a s e o t , s g e l ) e d i m e s o r u f n o i s s e r p e d r o a i n a m m u i h t i L valdecoxib and aspirin) Injectable gold Antihypertensives (such as methyldopa, clonidine, moxonidine) high blood pressure n i a p t s e h c , e s a e s i d t r a e h s e t a r t i n r e h t o r o n i r e c y l g o r t i N Antidiabetics (insulin), oral antidiabetics (metformin, pioglitazone) diabetes Thrombolytics (clopidogrel); beta blockers (bisoprolol, metoprolol) heart attack, high blood pressure Tricyclic antidepressants (such as amitriptyline); neuroleptics (such as phenothiazines or butyrophenones) depression and mental disorders l a i r e t c a b o c y m r e h t o d n a , ) B T s a n w o n k ( s i s o l u c r e b u t n i c i p m a f i R infections n o i t s e g i d n i d i c a d n a h c a m o t s sore , n r u b t r a e h ) e l o z a r p o t n a p , e n i d i t i n a r ( s d i c a t n A Sympathomimetics (medicines that stimulate the central nervous system) such as ephedrine, salbutamol (which may also be found in some cough/cold remedies) and noradrenaline or adrenaline low blood pressure, shock, heart failure, asthma or allergies h g i h r o s e n o t s y e n d i k f o t n e m t a e r t , t u o g f o n o i t n e v e r p l o n i r u p o l l A levels of uric acid e t a r t r a e h d i p a r a w o l s o t d n a s t a e b t r a e h r a l u g e r r i e d i m a n i a c o r P Anaesthetics (agents suppressing nerve impulses) used when you undergo surgery, even at the dentist Immunosuppressants (medicines that suppress the body’s immune response) used e.g. when you have had a recent organ transplant PACKAGE LEAFLET: INFORMATION FOR 전체 문서 읽기
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tanatril 20 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Imidapril hydrochloride 20 mg Excipient with known effect: Lactose, 90 mg per tablet For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets Off-white oblong biconvex tablets with a plane edge, scored on both sides. The tablet can be divided into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tanatril is indicated for the treatment of essential hypertension in adults. (See sections 4.3, 4.4, 4.5 and 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology- _Adults_ Treatment should be initiated with 5 mg once a day. If optimum control of blood pressure has not been achieved after at least 3 weeks of treatment, the daily dose should be increased to 10 mg, which has been determined to be the most effective daily dose. However, in a small number of patients it might be necessary to increase the daily dose to 20 mg (recommended maximum dose) or preferably, to consider combination therapy with a diuretic. It has not been assessed whether hypertensive patients would benefit from a combination of imidapril with other antihypertensive therapies. (See sections 4.3, 4.4, 4.5 and 5.1). - _Older People_ (65 years or older) The initial dose is 2.5 mg once a day. The dose should be titrated according to blood pressure response. The recommended maximum dose is 10 mg once a day. - _Patients with renal impairment_ Imidapril and its pharmacologically active metabolite, imidaprilat, are predominantly excreted via the kidney. Renal function should be evaluated before commencing therapy with imidapril in patients suspected of renal impairment. Creatinine clearance may be determined prior to treatment by using the formula of COCKROFT & GAULT (Nephron 1976; 16: 31-41): Cl Crea = (140-age [years]) x body weight [kg] 72 x serum creatinine [mg/dl] (for women the resulting value will be multiplied with 0.85; if the unit μ mol/l is used instead of mg/dl, 72 will be repl 전체 문서 읽기